Skip to main content
. Author manuscript; available in PMC: 2022 Nov 23.
Published in final edited form as: Circulation. 2021 Oct 21;144(21):1714–1731. doi: 10.1161/CIRCULATIONAHA.121.053575

Table 1.

Characteristics of 42 subjects included in the cohort.

Control Disease
Group Donor Mitral Stenosis HCM
NO. of patient samples 13 2 27
Female, n (%) 9 (69) 2 (100) 6 (22)
Age, year 50 ± 10 49 ± 6 54 ± 14
Positive Family Hx, n (%) 8 (30)

Mutations *
MYBPC3, n (%) 7 (28)
MYH7, n (%) 3 (12)
Others**,***, n (%) 2 (8)
VUS or no mutation, n (%) 13 (52)

Medication
β-blocker, n (%) 11 (41)
Calcium blocker, n (%) 19 (71)
Statin, n (%) 14 (52)

Echocardiogram
LVEF 58 ± 6 62 ± 6 67 ± 7
IVSd, cm 1.8 ± 0.5
LVPWd, cm 1.4 ± 0.4
IVSd/LVPWd ratio 1.4 ± 0.6
LVOT peak grad 40-60 mmHg, n (%) 2 (8)#
LVOT peak grad 60-90 mmHg, n (%) 4 (15)
LVOT peak grad > 90 mmHg, n (%) 20 (75)
LV Mass (ASE Method), g/m2; (LV mass index) 264 ± 100; (134 ± 45)##

Magnetic resonance imaging (MRI)
Delayed Enhancement (range) 1.5 ± 1.7 (0 - 4)
LV Mass, g/m2; (LV mass index) 187 ± 43; (94 ± 18)$

Continuous variables are expressed as mean ± SD and categorical variables as number (percentage); normal LV mass index28 in men, 70.0 ± 8.9 g/m2 and in women, 60.7 ± 8.1 g/m2.

*

Genetic testing was performed on 25 patients.

**

one patient had two mutations.

***

mutations in TNNT, CSRP, and SCN.

#

in one patient with a resting gradient of 33 mmHg, exercise gradient was not available.

##

left ventricular mass on 24 patients calculated from echo data.

$

left ventricular mass on 9 patients calculated from MRI data.

HCM, hypertrophic cardiomyopathy; MYBPC, myosin binding protein C; MYH, myosin heavy chain; VUS, variants of unknown significance; LVEF, left ventricular ejection fraction; IVSd, interventricular septum diameter in diastole; LVPWd, left ventricular posterior wall thickness in diastole; LVOT peak grad, left ventricular outflow tract peak gradient; ASE, American Society of Echocardiography.